کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5701058 1601353 2017 26 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Developments in targeted therapy in melanoma
ترجمه فارسی عنوان
پیشرفت در درمان هدفمند در ملانوم
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
چکیده انگلیسی
The successful development of kinase inhibitors marked a milestone in the treatment of metastatic melanoma. Combination treatment with a BRAF- and MEK-inhibitor is the current standard of care for inoperable stage IIIC/IV BRAF-mutated melanoma. Recent data demonstrate excellent long-term outcome, especially in patients with normal baseline LDH levels, and confirm that there is a subset of BRAF inhibitor-naive patients who experience durable responses without progression on combination treatment. In the future, adding a third compound based on individual genetic alterations might further improve the outcome of targeted therapy.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Surgical Oncology (EJSO) - Volume 43, Issue 3, March 2017, Pages 581-593
نویسندگان
, , , , , , , ,